Gilead Sciences stock has quietly turned in a strong run over the past five years, yet on traditional valuation checks it still screens as inexpensive relative to its fundamentals. This raises the question of whether the market is fully reflecting that track record and the current news flow.

• Gilead Sciences has returned 126.8% over 5 years, which puts its recent share price strength front and center in any discussion of value.
• On the fundamental side, expectations around the HIV portfolio, including new research being presented at AIDS 2026, can support sentiment, while mixed clinical outcomes and execution risks in newer oncology efforts may limit how much investors are willing to pay for the stock.
• The company looks undervalued on a broad set of checks, with a high value score of 5 out of 6, which suggests the broader valuation framework leans cheap rather than fully priced.

The issue now is whether Gilead Sciences' current share price still offers a margin of value appeal after this performance and the latest pipeline and sentiment shifts.

Is Gilead Sciences a Bargain on Earnings?

P/E is a useful way to look at Gilead Sciences because the stock is covered closely on earnings and trades in a sector where this metric is widely used. Gilead Sciences currently trades on a P/E of 17.6x, which is very close to the biotech industry average of about 17.2x and well below the peer group average of 48.7x. On raw market comparisons, the stock sits around the sector norm rather than at a premium.

Using a tailored fair P/E of 32.7x, which reflects Gilead Sciences' mix of HIV cash flows, oncology ambitions and risk profile, the current multiple appears to sit at a sizable discount to where this model-based ratio would place it. Despite the recent pressure after mixed earnings and an oncology trial setback, the market is still assigning a P/E that is well under this fair ratio.

On the P/E multiple, Gilead Sciences stock appears undervalued relative to what its earnings profile and risk mix might typically justify.

The Gilead Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Gilead Sciences pick up where the valuation checks stop by spelling out the earnings, margin and growth paths that would need to unfold for the stock to be worth materially more or less than today’s price on the Community page. Where a single ratio or model offers one valuation number, these scenarios lay out the future those numbers rely on so you can watch how closely reality tracks the assumptions.

Community views on Gilead Sciences split between a pipeline driven upside story and concerns that recent deal activity and competition already justify the current price.

Bull case: 28% undervalued

"Gilead’s upcoming launches, including twice-yearly lenacapavir for PrEP, anito-cel cell therapy for multiple myeloma, and Trodelvy’s move into first-line triple-negative breast cancer, positively position the company to capture significantly larger addressable markets…"

Bear case: roughly fairly valued

"Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution."

Do you think there's more to the story for Gilead Sciences? Head over to our Community to see what others are saying!

The Bottom Line

Gilead Sciences screens as undervalued on market multiples, with its current P/E sitting below the tailored fair ratio that reflects its mix of established HIV cash flows and higher risk oncology projects. That discount appears tied to the question of how much credit investors should give to newer programs after mixed trial outcomes and deal activity.

From here, the key judgment is whether the HIV franchise and selected pipeline launches can offset execution risk in oncology. The central question is whether today’s valuation gap represents a genuine opportunity or indicates that the market is correctly pricing the probability of slower progress.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.